We have shown that VRK1 depletion sensitizes tumor cells to two types of pharmacological treatments, temozolomide, a drug used in glioblastoma, and olaparib, an inhibitor of PARP-1 that is in use for the treatment of tumors with BRCA1 mutations (Tewari et al., 2015; Robson et al., 2017; Golan et al., 2019). The gene discussed is PARP1; the disease is glioblastoma.